Aarti Pharmalabs Ltd (AARTIPHARM) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Aarti Pharmalabs Ltd reported record-breaking quarterly performance with the highest ever quarterly profit in the company's history on both standalone and consolidated basis.
- Consolidated top line reached Rs. 538 crores, a 20% Y-o-Y increase.
- EBITDA grew by 34% Y-o-Y, reaching Rs. 129 crores.
- Profit after tax surged by 40% Y-o-Y, reaching Rs. 74 crores.
- All three business segments – Xanthine derivatives, API Intermediates, and CDMO/CMO – performed well.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.